Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
829.00    9.00 (1.10%)
Bid:
827.00
Ask:
833.00
Spread: 6.00 (0.726%)
Market Cap: £782.94m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AuM Update

10 Oct 2019 07:00

RNS Number : 3525P
Polar Capital Holdings PLC
10 October 2019
 

10 October 2019

 

Polar Capital Holdings plc

AuM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides its quarterly update of its unaudited statement of its Assets under Management ("AuM").

 

 

Group AuM (unaudited)

 

Polar Capital reports that as at 30 September 2019 its AuM were £14.3bn compared to £13.8bn at the end of March 2019, an increase of 3% over the period. During the period, AuM increased by £467m which comprised net outflows of £448m offset by an increase of £915m related to market movement and fund performance.

 

AuM movement in six months

to 30 September 2019

Long only

funds

Alternative funds

Total

AUM at 1 April 2019

£12,529m

£1,306m

£13,835m

Net subscriptions / (redemptions)

£(560)m

£112m

£(448)m

Market movement and

performance

£868m

£47m

£915m

Total AuM at 30 September 2019

£12,837m

£1,465m

£14,302m

 

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fee profits due to the Group (after the deduction of staff interests) as a product of accrued performance fees in funds managed by the Group three months before the strike point of such performance fee receipts. The majority of the Group's performance fees crystallise in the second half of the financial year.

 

Performance fees

net of staff allocations

Six months to

30 Sept 18

 

 

Year to

31 Mar 19

(year-end)

 

Six months to

30 Sept 19

 

 

Received

 

£5.5m

£24.0m

£3.3m

Accrued but not yet earned in funds with year ends on or before the financial year end

£27.0m

n/a

£0.9m*

Total net performance fee profits

£32.5m

£24.0m

 

£4.2m*

 

 

*the figures are reduced by £2m of net performance fee distributions that relate to prior accounting periods that IFRS require to be deducted from this year's receipts.

 

 

 

As is usual at the time of releasing this update, three months before the crystallisation of performance fees, we disclose the profits that could be due to Polar as a function of the amount of accrued performance fees in our funds as at the end of September. There is no certainty that the fees will be sustained over the next quarter, as performance fee receipts are extremely volatile.

 

Gavin Rochussen, Chief Executive, commented:

 

"The last quarter has been a challenging period with net outflows of £598m following the £150m of net inflows in the previous quarter.

 

"As communicated at the time of releasing our year-end results in June, the Japan team has undergone changes following the departure of the long-standing manager of our Japan Fund. The team is focused on the Japan Value Fund which has compelling performance and will benefit from greater AuM following the imminent merger of the two funds. Net outflows in the six months from the Japan Fund following the communication of the manager departure and fund merger have been £400m. As at 30 September, the Japanese equities team was managing £314m.

 

"In the six months, two long-standing clients redeemed in excess of £500m from two of our highly rated funds, the Polar Capital Technology Fund and the Polar Capital Healthcare Opportunities Fund to take profits and reduce risk in their underlying client portfolios. This has provided the Technology and Healthcare strategies with additional capacity where the demand for their funds is robust.

 

"Notwithstanding the £900m headwind created by the Japan Fund redemptions and the client redemption from Technology and Healthcare, it is reassuring that, despite the economic and political uncertainty over the last six months, we have had net inflows into the majority of our funds including: Global Insurance, UK Value, European Income and Emerging Market and Asia with positive net inflows of £112m into our alternative fund range which includes our Convertibles and UK Absolute products.

 

"While accrued performance fees are materially less than the previous year, fees are volatile, and the position three months ago was more in line with last year. There are still three months to the end of the calendar year when performance fees crystallise. We remain confident that our active fundamental fund strategies will continue to deliver above average returns over the long term for our clients."

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)John Mansell (Executive Director)

Samir Ayub (Finance Director)

 

 

+44 (0)20 7227 2700

Numis Securities Limited - Nomad and Joint Broker

Charles Farquhar

Stephen Westgate

Kevin Cruickshank (QE)

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Guy Wiehahn

Andrew Buchanan

 

+44 (0)20 7418 8893

 

Camarco

Ed Gascoigne-Pees

Monique Perks

 

 

+44 (0)20 3757 4995

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDMLBATMBJMBAL
Date   Source Headline
29th Sep 202012:19 pmRNSHolding(s) in Company
18th Sep 202011:20 amRNSForm 8.3 - HASTINGS GROUP HOLDINGS PLC
10th Sep 202012:26 pmRNSForm 8.3 - HASTINGS GROUP
6th Aug 20203:31 pmRNSForm 8.3 - HASTINGS GROUP HOLDINGS PLC
3rd Aug 20207:00 amRNSBlock listing Interim Review
3rd Aug 20207:00 amRNSTotal Voting Rights
31st Jul 20207:30 amRNSIssue of Equity
30th Jul 20205:23 pmRNSForm 8.3 - HASTINGS GROUP HOLDINGS PLC
29th Jul 20207:00 amRNSResult of AGM
22nd Jul 20204:15 pmRNSIssue of Equity
22nd Jul 202012:10 pmRNSDirector/PDMR Shareholding
10th Jul 20202:07 pmRNSDirector/PDMR Shareholding
10th Jul 20202:06 pmRNSDirector/PDMR Shareholding
9th Jul 20207:00 amRNSAuM Update
7th Jul 20208:03 amRNSHolding(s) in Company
6th Jul 202010:08 amRNSDirector/PDMR Shareholding
3rd Jul 20207:00 amRNSForm 8.3 - Cello Health PLC
2nd Jul 20209:19 amRNSDirector/PDMR Shareholding
1st Jul 20202:10 pmRNSIssue of Equity
1st Jul 20207:00 amRNSTotal Voting Rights
29th Jun 202010:03 amRNSDirector/PDMR Shareholding
26th Jun 20201:10 pmRNSAnnual Financial Report
25th Jun 202010:26 amRNSHolding(s) in Company
25th Jun 202010:25 amRNSDirector/PDMR Shareholding
24th Jun 20203:29 pmRNSIssue of Equity
22nd Jun 20204:04 pmRNSDividend Declaration
22nd Jun 20207:00 amRNSGroup Audited Results for year ended 31 March 2020
18th Jun 202012:08 pmRNSSecond Price Monitoring Extn
18th Jun 202012:02 pmRNSPrice Monitoring Extension
5th Jun 202010:31 amRNSDirector/PDMR Shareholding
4th Jun 20207:16 amRNSNotice of Results
1st Jun 20207:00 amRNSTotal Voting Rights
19th May 20202:00 pmRNSIssue of Equity
12th May 202010:22 amRNSDirector/PDMR Shareholding
11th May 20201:15 pmRNSDirectorate Change
6th May 202011:36 amRNSHolding(s) in Company
4th May 20201:07 pmRNSIssue of Equity
4th May 202011:24 amRNSDirector/PDMR Shareholding
15th Apr 202012:00 pmRNSFund Termination
9th Apr 20204:26 pmRNSDirectorate Change
9th Apr 202012:02 pmRNSHolding(s) in Company
9th Apr 20207:00 amRNSAuM Update
7th Apr 20204:40 pmRNSSecond Price Monitoring Extn
7th Apr 20204:35 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSBoard Changes
1st Apr 20207:00 amRNSTotal Voting Rights
30th Mar 202012:08 pmRNSSecond Price Monitoring Extn
30th Mar 202012:02 pmRNSPrice Monitoring Extension
19th Mar 20204:41 pmRNSSecond Price Monitoring Extn
19th Mar 20204:37 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.